My interview with Can-Fite (NYSEMKT:CANF) Chief Executive Officer Dr. Pnina Fishman is the latest in my series of interviews with under-covered Israeli companies that trade on U.S. exchanges. It is posted exclusively on Seeking Alpha.
- Can-Fite’s advanced-stage drug targets a $45b worldwide anti-rheumatics market.
- A strong intellectual property portfolio offers long-term potentials.
- A platform approach to drug creation could lead to big-pharma collaborations.
CEO cited positive data from its Phase II Rheumatoid Arthritis clinical study and from an interim analysis of the Psoriasis Phase II/III study as key achievements of the last 12 months.
The shares of the micro-cap stock have more than halved from their high on Dec. 13, 2013. Management is scheduled to present at the Rodman & Renshaw Global Investment Conference on September 9.